How long is Winlevi’s patent protection?
Winlevi (tretinoin?) is an FDA-approved topical acne treatment (brand name Winlevi; active ingredient clascoterone). The exact time left on “the Winlevi patent” depends on which specific patent is being asked about (drug substance, formulation, method-of-use, or patents covering exclusivity), because multiple patents can cover the product and they expire on different dates.
DrugPatentWatch.com tracks these patent and exclusivity details for branded drugs and is typically the quickest way to identify the relevant listed patents and their expiration timelines for Winlevi. You can check the current listing here: DrugPatentWatch – Winlevi patents.
When would generic or biosimilar versions be able to enter?
Even after a particular patent expires, market entry can still be blocked by other remaining patents or by regulatory exclusivity periods. So the practical answer to “how long” usually means: the last date when the full set of relevant barriers (the latest expiring patent(s) and any applicable exclusivity) clears.
For the most accurate “earliest possible entry” date, you need the latest expiring patent(s) in the Orange Book/patent listings for Winlevi and any additional exclusivity constraints—again, DrugPatentWatch compiles this in one place. DrugPatentWatch – Winlevi patents.
Which patent should you look at?
People often ask this question intending one of these:
- “How long until the brand’s main drug patent expires?”
- “When do all patents covering Winlevi end?”
- “When can generic topical clascoterone launch?”
Those answers can differ because each patent family and claim set can have different expiration dates.
Can you tell me which “Winlevi patent” you mean?
If you share whether you mean the drug’s main composition-of-matter patent, a formulation/method-of-use patent, or just the overall “last patent expiry,” I can help interpret what that specific expiration date means for generic entry—using the relevant DrugPatentWatch listing.